Tyra Biosciences Inc
Company Profile
Business description
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Contact
2656 State Street
CarlsbadCA92008
USAT: +1 619 728-4760
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
87
Stocks News & Analysis
stocks
SpaceX is scaling AI infrastructure on earth, data centers in space might be next
stocks
Investors too optimistic about overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.10 | 39.50 | -0.44% |
| CAC 40 | 7,830.75 | 90.93 | -1.15% |
| DAX 40 | 25,454.28 | 190.76 | -0.74% |
| Dow JONES (US) | 52,856.09 | 360.21 | 0.69% |
| FTSE 100 | 10,720.52 | 32.36 | -0.30% |
| HKSE | 22,934.68 | 717.19 | -3.03% |
| NASDAQ | 26,702.86 | 278.04 | 1.05% |
| Nikkei 225 | 62,907.84 | 1,713.40 | -2.65% |
| NZX 50 Index | 13,746.84 | 14.45 | -0.11% |
| S&P 500 | 7,757.17 | 44.60 | 0.58% |
| S&P/ASX 200 | 8,793.20 | 38.10 | -0.43% |
| SSE Composite Index | 3,658.03 | 55.00 | -1.48% |